Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract

Area of Science:

• Medicinal Chemistry
• Microbiology
• Drug Discovery

Background:

• Gastrointestinal (GI) tract colonization by pathogenic bacteria causes severe healthcare-associated infections.
• Developing effective GI decolonization agents remains a significant challenge.
• Targeting pathogens within the GI tract requires specialized antimicrobial properties.

Purpose of the Study:

• To modify 1,2,4-oxadiazole antimicrobial compounds for GI tract targeting.
• To identify analogues with impermeability and activity against key GI pathogens.
• To evaluate the potential of these modified compounds as colon-targeted antimicrobial agents.

Main Methods:

• Modification of 1,2,4-oxadiazole compounds with poorly permeable functional groups.
• Assessment of compound impermeability using Caco-2 cell monolayers.
• Evaluation of antimicrobial activity against Clostridioides difficile and multidrug-resistant Enterococcus faecium.
• Oral administration studies in rats to assess compound recovery.

Main Results:

• Analogue 26a, featuring a quaternary ammonium group, demonstrated complete impermeability in Caco-2 cells.
• Analogue 26a retained potent activity against Clostridioides difficile and multidrug-resistant Enterococcus faecium.
• Low compound recovery levels were observed after oral administration in rats, suggesting potential gut degradation or metabolism.

Conclusions:

• Modified 1,2,4-oxadiazole analogues show potential as colon-targeted antimicrobial agents.
• Analogue 26a is a promising lead compound for developing GI decolonization strategies.
• Further optimization is needed to address potential in vivo degradation and improve efficacy.